Valuation: Adocia SA

Market Cap 44.02M 49.56M 41.17M 37.52M 70.63M 4.77B 71.6M 498M 193M 2.43B 186M 182M 7.81B P/E 2026 *
-2.74x
P/E 2027 * 3.25x
Enterprise Value 48.42M 54.52M 45.28M 41.27M 77.69M 5.25B 78.76M 548M 212M 2.67B 205M 200M 8.59B EV / Sales 2026 *
-
EV / Sales 2027 * 1.65x
Free-Float
96.05%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 11/05/2023
Director of Finance/CFO - 23/09/2024
Chief Tech/Sci/R&D Officer - 01/12/2014
Director TitleAgeSince
Director/Board Member 55 19/04/2013
Chairman 57 -
Director/Board Member 61 11/05/2023
Change 5-day change 1-year change 3-year change Capi.($)
+20.41%-.--% - - 54.88M
+4.16%+3.04%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+82.72% 60.14B
-2.54%-1.65%+4.86%+31.72% 48.15B
-3.02%-5.20%+27.94%+32.51% 44.25B
+0.31%+3.02%+348.95%+643.82% 43.99B
-1.96%-0.33%+7.04%+99.46% 41.61B
+3.32%+3.49%+10.10%+51.23% 29.97B
-3.57%+1.98%+28.45%+21.60% 29.31B
-4.86%-10.66%-26.27%+330.06% 24.93B
Average +1.16%-0.08%+53.08%+154.14% 44.09B
Weighted average by Cap. -0.44%+0.11%+57.74%+145.69%

Financials

2026 *2027 *
Net sales - 44.87M 50.51M 41.96M 38.24M 71.98M 4.86B 72.97M 508M 196M 2.48B 190M 186M 7.96B
Net income -16M -18.01M -14.96M -13.64M -25.67M -1.73B -26.02M -181M -70.07M -883M -67.63M -66.17M -2.84B -44.33M -49.91M -41.45M -37.78M -71.12M -4.81B -72.1M -501M -194M -2.45B -187M -183M -7.86B
Net Debt 4.4M 4.95M 4.11M 3.75M 7.06M 477M 7.16M 49.78M 19.27M 243M 18.6M 18.2M 780M 30.18M 33.97M 28.22M 25.72M 48.41M 3.27B 49.08M 341M 132M 1.67B 128M 125M 5.35B
Logo Adocia SA
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
73
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.250EUR
Average target price
9.700EUR
Spread / Average Target
+331.11%

Quarterly revenue - Rate of surprise